Permanent Prostate Brachytherapy in Men with Clinically Localised Prostate Cancer (Q35549673)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14524482 AND SRC:MED&resulttype=core&format=json

19 December 2019

review article

1 reference

title

Permanent prostate brachytherapy in men with clinically localised prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14524482 AND SRC:MED&resulttype=core&format=json

19 December 2019

Permanent Prostate Brachytherapy in Men with Clinically Localised Prostate Cancer (English)

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

17 March 2024

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

17 March 2024

1

Potters L

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14524482 AND SRC:MED&resulttype=core&format=json

19 December 2019

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14524482

17 March 2024

publication date

1 September 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14524482 AND SRC:MED&resulttype=core&format=json

full work available at URL

19 December 2019

https://api.elsevier.com/content/article/PII:S0936655503001523?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

https://api.elsevier.com/content/article/PII:S0936655503001523?httpAccept=text/plain

17 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

17 March 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14524482 AND SRC:MED&resulttype=core&format=json

19 December 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14524482 AND SRC:MED&resulttype=core&format=json

19 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14524482 AND SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

301-315

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14524482 AND SRC:MED&resulttype=core&format=json

19 December 2019

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Incidence rate and management of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994.

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

I-125 interstitial implantation for prostate cancer. What have we learned 10 years later?

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

The history of interstitial brachytherapy of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

An improved method for computerized tomography-planned transperineal 125iodine prostate implants

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

A dose-response study for I-125 prostate implants

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Relationship between the transition zone index of the prostate gland and urinary morbidity after brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Prostate brachytherapy in patients with prostate volumes >/= 50 cm(3): dosimetic analysis of implant quality

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Use of a modified American Urological Association Symptom Score for the evaluation of the quality of life of patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Isotope selection for patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Prostate brachytherapy: importance of technique

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy.

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Prostate volumes and organ movement defined by serial computerized tomographic scans during three-dimensional conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Timing of Computed Tomography–Based Postimplant Assessment Following Permanent Transperineal Prostate Brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate.

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

CT-based dosimetry for transperineal I-125 prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate.

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Urinary Incontinence in Patients Who Have a TURP/TUIP Following Prostate Brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Patient reported complications after prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Efficacy of digital rectal examination after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Acute urinary morbidity following I-125 interstitial implantation of the prostate gland

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

The dosimetry of prostate brachytherapy-induced urethral strictures

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

The effect of constipation on rectal dosimetry following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

High dose combination radiotherapy for the treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Clinical course of rectal bleeding following I-125 prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Rectal function following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Rectal dosimetric analysis following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Potency after permanent prostate brachytherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Use of TRUS to predict pubic arch interference of prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Permanent seed implantation for localized adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Strategies for improving the outcome of patients with poor prognosis prostate cancers

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10)

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Neoadjuvant hormonal therapy in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

7 January 2021

Permanent prostate brachytherapy: lessons learned, lessons to learn

4

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy

17 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer

17 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone

17 March 2024

71

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

Neoadjuvant Hormonal Therapy Improves the Outcomes of Patients Undergoing Radioactive Seed Implantation for Localized Prostate Cancer

17 March 2024

83

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis

17 March 2024

93

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations

17 March 2024

96

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

Intraoperative dosimetric representation of the real-time ultrasound-guided prostate implant

17 March 2024

99

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00152-3

17 March 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14524482 AND SRC:MED&resulttype=core&format=json

19 December 2019

1 reference